Denver, Colorado – Markets are opening Thursday with a mix of defense innovation, biotech progress, aerospace supply chain momentum, and turnaround earnings, highlighting how technology and strategic manufacturing continue to drive investor attention across several sectors. From next-generation biomaterials to counter-drone systems and aerospace electronics, the latest corporate developments suggest continued capital flow toward industries tied to national security, healthcare innovation, and advanced manufacturing.
One of the most notable updates came from Kraig Biocraft Laboratories (OTCQB:KBLB), which announced a major milestone in its ambitious Project Atlas bioengineering initiative. Meanwhile, Impact Biomedical (NYSE:IBO) gained attention following changes to its merger agreement with Dr Ashleys Bio Labs Limited, while Gaxos.ai (NASDAQ:GXAI) highlighted progress in counter-drone defense technology through its stake in America First Defense.
Additional developments included aerospace component orders for Mobix Labs (NASDAQ:MOBX), encouraging clinical trial results from BioXcel Therapeutics (NASDAQ:BTAI), and a sharp financial turnaround reported by Alto Ingredients (NASDAQ:ALTO).
Spider Silk Technology Reaches a New Milestone
Advanced materials developer Kraig Biocraft Laboratories (OTCQB:KBLB) reported that its Project Atlas initiative has passed a critical development milestone, marking progress toward creating entirely new classes of biomaterials designed for industrial and defense applications.
The project, first disclosed in January 2026, aims to merge numerous complex genetic elements into a single integrated architecture capable of producing spider-silk-based super fibers with enhanced strength and toughness. According to the company, the program has already generated several new transgenic lines that are now moving through its internal evaluation pipeline as it advances toward scalable production.
The update comes amid growing attention to Kraig Labs’ work in bioengineered spider silk, highlighted by its recent appearance on the cover of the March 2026 issue of National Geographic Society’s flagship publication, https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering. As global interest in lightweight, high-performance materials expands, particularly in defense, aerospace, and medical fields, advances like Project Atlas illustrate how biotechnology may redefine the future of advanced textiles.
24/7 Market News encourages readers and industry observers to obtain a copy of this month’s National Geographic to review the full feature and explore the scientific context in depth. Interested persons can order a copy of the magazine from National Geographic at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.
Impact Biomedical Advances Merger Plans
Shares of Impact Biomedical (NYSE:IBO) moved higher after the company disclosed amendments to its pending merger agreement with Cayman Islands-based pharmaceutical firm Dr Ashleys Bio Labs Limited.
The updated filing extends the transaction deadline from March 31 to July 1, 2026. Under the revised terms, Dr Ashleys Limited will issue approximately 169.5 million ordinary shares to its sole shareholder at closing, representing about 94.2% of the company’s total outstanding shares.
Parent company DSS (NYSE:DSS), which holds a significant stake in Impact Biomedical, will receive 53,000 ordinary shares at closing to satisfy hold-harmless obligations, with the potential for an additional 75,000 shares if funding requirements under a revised transition arrangement are met. The restructuring highlights ongoing consolidation activity within the global pharmaceutical sector as companies seek scale and expanded product pipelines.
Counter-Drone Defense Technology Gains Momentum
Defense technology also moved into the spotlight after Gaxos.ai (NASDAQ:GXAI) announced that America First Defense secured a license for the Detachable Drone Highjacker, a counter-UAS system originally developed at the Naval Postgraduate School.
Unlike traditional counter-drone systems that rely on signal jamming, the technology is designed to attach to a friendly drone and neutralize hostile unmanned aircraft through targeted cyber operations. This selective approach aims to defeat enemy drones while minimizing interference with surrounding communications systems.
Gaxos.ai holds a stake in America First Defense, positioning the company within the rapidly expanding counter-UAS market. As drone warfare and security threats continue to evolve globally, demand for advanced drone defense platforms has accelerated across military, homeland security, and critical infrastructure sectors.
Aerospace Supply Chains Continue to Drive Orders
In aerospace manufacturing, Mobix Labs (NASDAQ:MOBX) reported new production purchase orders tied to ongoing aircraft manufacturing for Gulfstream Aerospace business jets.
Mobix supplies high-reliability electronic components designed to protect sensitive onboard aircraft systems from electromagnetic interference. Because the company’s technology is already integrated into existing Gulfstream platforms, continued aircraft production can generate recurring orders as manufacturing schedules progress.
The company noted that suppliers embedded within active aerospace platforms often benefit from long production cycles that can extend for decades. Mobix technologies are also deployed across multiple defense systems, including the F-22 Raptor fighter aircraft and AH-64 Apache helicopters, underscoring the firm’s footprint across high-reliability military electronics.
Biotech Trial Results Address the Opioid Crisis
Healthcare innovation was another focal point as BioXcel Therapeutics (NASDAQ:BTAI) reported positive Phase 2 topline results for BXCL501, a treatment candidate targeting opioid withdrawal symptoms.
The study, funded by the National Institute on Drug Abuse, suggested the therapy may match or exceed the effectiveness of Lucemyra while demonstrating favorable tolerability and a simpler dosing regimen.
The research arrives at a time when opioid use disorder remains a major global health challenge. Approximately 5.9 million adults in the United States are estimated to have the condition, highlighting the need for improved treatment options that can help patients successfully transition to long-term therapies.
Renewable Fuels Company Reports Strong Turnaround
Meanwhile, Alto Ingredients (NASDAQ:ALTO) reported a dramatic improvement in its fourth-quarter and full-year 2025 financial results.
The renewable fuels and specialty alcohol producer posted fourth-quarter gross profit of $15.2 million, compared with a gross loss of $1.4 million a year earlier. Net income for the quarter reached $21.5 million, or $0.28 per share, representing a $63.5 million improvement year-over-year.
The company attributed the turnaround to stronger crush margins, renewable fuel exports, and the generation of federal 45Z clean fuel production credits. Management said the restructuring efforts completed during 2025 have positioned the company with a leaner cost structure and clearer strategy heading into 2026.
Please click here to read the full Kraig Labs analyst report on 247marketnews.com.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions.
For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
OTCQB:KBLB, NYSE:IBO, NASDAQ:GXAI, NASDAQ:MOBX, NASDAQ:BTAI, NASDAQ:ALTO